FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Ad

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/12/2026

1. CRWV
2. SMCI
3. LITE
4. ONON
5. CAVA
6. AMC
7. NCMI
8. FOCL
9. TME
10. CNK

Go back to FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Ad
Merck & Co. (NYSE: MRK) Delayed: 130.42 --0 (-0%)
Previous Close $130.42    52 Week High $65.46 
Open $130.42    52 Week Low $47.97 
Day High $130.42    P/E 88.72 
Day Low $130.42    EPS $1.47 
Volume 4,988